A potential rheumatoid arthritis therapy is one step closer to approval.
Researchers from GlaxoSmithKline (GSK), a pharmaceutical company based in London, completed a phase III study on sirukumab, a human anti-interleukin (IL)-6 monoclonal antibody, and the initial results were positive.
GSK is developing sirukumab in partnership with Ireland-based pharmaceutical company Janssen Biologics. The phase III study began in Aug. 2012.
Rheumatoid arthritis is a chronic, systemic inflammatory disease marked by pain, stiffness and inflammation of the joints. The condition often leads to joint destruction.
Studies on sirukumab are ongoing — the long-term safety and effectiveness of sirukimab have not yet been determined. Findings from the three studies already conducted will be presented at upcoming medical and scientific conferences and will be submitted to medical journals for possible publication.
The therapy has not been approved for use in any country, but it is anticipated that regulatory applications will be submitted in 2016.
More information about the studies on sirukumab can be found online at www.gsk.com.
